Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted DA-EPOCH-R as first-line therapy in adult Burkitt lymphoma
2012-003141-16Phase 2Active
- Sponsor
- VU University Medical Center
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone in Burkitt lymphoma (BL), sponsored by VU University Medical Center. Started Aug 2012; status: active.
02
Drugs
etoposidedoxorubicinvincristinecyclophosphamideprednisolone
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2012-003141-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003141-16.